Bacthera was a specialized CDMO focused on live biotherapeutic products (LBPs) and microbiome-based therapeutics, operating as a joint venture that originated from Lonza and Chr. Hansen. The company provided development and cGMP manufacturing services across the live biotherapeutics value chain, from drug substance production through drug product manufacturing. Bacthera collaborated with Seres Therapeutics for commercial manufacturing of SER-109 (a treatment for recurrent C. difficile infection), acquired a cGMP site in Leon, Spain, and received regulatory approvals from Swissmedic and the Danish Medicines Agency. However, Bacthera ceased its CDMO operations by September 2025, with its equipment subsequently acquired by EXPERT'Biome (Lallemand's CDMO division). Note: this company has closed its CDMO operations.
live biotherapeutic product manufacturing, microbiome therapeutics, anaerobic fermentation, LBP drug substance and drug product, microbial strain banking
2 sites worldwide
No reviews available yet.
No documents available.